Related Experiment Video
Updated: Feb 20, 2026
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
Clinical trials of CAR-T cells in China
Bingshan Liu1,2, Yongping Song3, Delong Liu4
1School of Basic Medical Sciences and The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.
Abstract:
Novel immunotherapeutic agents targeting tumor-site microenvironment are revolutionizing cancer therapy. Chimeric antigen receptor (CAR)-engineered T cells are widely studied for cancer immunotherapy. CD19-specific CAR-T cells, tisagenlecleucel, have been recently approved for clinical application. Ongoing clinical trials are testing CAR designs directed at novel targets involved in hematological and solid malignancies. In addition to trials of single-target CAR-T cells, simultaneous and sequential CAR-T cells are being studied for clinical applications. Multi-target CAR-engineered T cells are also entering clinical trials. T cell receptor-engineered CAR-T and universal CAR-T cells represent new frontiers in CAR-T cell development. In this study, we analyzed the characteristics of CAR constructs and registered clinical trials of CAR-T cells in China and provided a quick glimpse of the landscape of CAR-T studies in China.
Insights
Chimeric antigen receptor (CAR)-T cell therapy is advancing cancer treatment. This study reviews CAR constructs and clinical trials in China, offering insights into the evolving landscape of CAR-T research.
Area of Science:
- Immunotherapy
- Oncology
- Cellular Therapy
Background:
- Novel immunotherapeutic agents are revolutionizing cancer therapy by targeting the tumor microenvironment.
- Chimeric antigen receptor (CAR)-engineered T cells represent a significant advancement in cancer immunotherapy.
- CD19-specific CAR-T cells (tisagenlecleucel) have gained recent clinical approval, highlighting the therapeutic potential.
Purpose of the Study:
- To analyze the characteristics of CAR constructs used in cancer immunotherapy.
- To review registered clinical trials of CAR-T cells in China.
- To provide an overview of the current landscape of CAR-T cell studies in China.
Main Methods:
- Analysis of CAR construct characteristics.
- Systematic review of registered CAR-T cell clinical trials in China.
- Landscape analysis of CAR-T cell research.
Main Results:
- Ongoing clinical trials are exploring novel CAR designs for various malignancies.
- Simultaneous, sequential, and multi-target CAR-T cell strategies are under investigation.
- Emerging frontiers include T cell receptor-engineered CAR-T and universal CAR-T cells.
Conclusions:
- CAR-T cell therapy is a rapidly developing field with diverse strategies being explored.
- China is actively involved in CAR-T cell research and clinical trials.
- Further research into CAR constructs and clinical applications holds promise for cancer treatment.
